Breast Cancer Research and Treatment

, Volume 61, Issue 2, pp 145–150

Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer

Authors

  • Hitoshi Okamura
    • Psycho-Oncology DivisionNational Cancer Center Research Institute East
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Noboru Yamamoto
    • Department of Medical OncologyNational Cancer Center Hospital
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Toru Watanabe
    • Department of Medical OncologyNational Cancer Center Hospital
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Noriyuki Katsumata
    • Department of Medical OncologyNational Cancer Center Hospital
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Shigemitsu Takashima
    • Department of SurgeryNational Shikoku Cancer Center Hospital
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Isamu Adachi
    • Department of Medical OncologyNational Cancer Center Hospital
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Akira Kugaya
    • Psycho-Oncology DivisionNational Cancer Center Research Institute East
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
  • Tatsuo Akechi
    • Psychiatry DivisionNational Cancer Center Hospital
  • Yosuke Uchitomi
    • Psycho-Oncology DivisionNational Cancer Center Research Institute East
    • the Breast Cancer Study Groupthe Japan Clinical Oncology Group (JCOG)
Article

DOI: 10.1023/A:1006491417791

Cite this article as:
Okamura, H., Yamamoto, N., Watanabe, T. et al. Breast Cancer Res Treat (2000) 61: 145. doi:10.1023/A:1006491417791

Abstract

Purpose: To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician.

Patientsandmethods: Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized phase III trial (Japan Clinical Oncology Group (JCOG) Study 8808) were asked whether they understood their own disease after being given information about the clinical trial. They were classified into two groups on the basis of whether they understood or not. We estimated their survival after the time of registration and derived relative hazard ratios from Cox's proportional hazards model.

Results: There were 190 patients in the ‘better understanding’ group and 24 in the ‘poor understanding’ group. Median survival times after registration were 28.3 and 16.1 months, respectively. The ‘better understanding’ group showed a significant difference from the ‘poor understanding’ group (p=0.016). In multivariate regression analysis, patients who did not understand still showed poorer survival than those who understood (hazard ratio = 2.09; 95% confidence interval (CI) 1.16–3.78; p=0.014)

clinical trialinformed consentmetastatic breast cancersurvivalunderstanding

Copyright information

© Kluwer Academic Publishers 2000